The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Semaglutide , a dual GIP/GLP-1 receptor agonist , alongside Surfactant , a triple GIP/GLP-1/GCG receptor agonist , https://thebookmarkid.com/story21752451/tirzepatide-and-nicotinamide-adenine-dinucleotide-a-triple-threat-system-to-general-health